Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: arginine hydrochloride; poloxamer; calcium chloride dihydrate; sodium citrate dihydrate; sucrose; sodium chloride - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 4000 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 3000 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - simoctocog alfa, quantity: 2500 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Malta - Ingliż - Medicines Authority

bio products laboratory limited - factor ix, human - powder for solution for injection - factor ix, human 50 international unit(s)/millilitre - antihemorrhagics

Stati Uniti - Ingliż - NLM (National Library of Medicine)

octapharma pharmazeutika produktionsgesellschaft m.b.h. - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is a von willebrand factor/coagulation factor viii complex (human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von willebrand disease (vwd) as well as patients with mild or moderate vwd in whom the use of desmopressin is known or suspected to be ineffective or contraindicated. clinical trials to evaluate the safety and efficacy of prophylactic dosing with wilate to prevent spontaneous bleeding have not been conducted in vwd subjects. wilate is not indicated for the prevention of excessive bleeding during and after surgery in vwd patients. wilate is not indicated for hemophilia a. wilate is contraindicated for patients who have known anaphylactic or severe systemic reaction to plasma-derived products, any ingredient in the formulation, or components of the container. for a complete listing of ingredients, see description ( 11 ). pregnancy category c. animal reproduction studies have not been conducted with wilate. it is also not known whether

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.